Galectin Therapeutics Inc.
GALTNASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $210.14M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $2.03$7.13
- Volume (live)
- -
- Avg. volume (3M)
- 246.39K
Galectin Therapeutics (GALT) Stock Price & Financial Analysis
Galectin Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $3.16 - $3.37 |
|---|---|
| 52-Week High | $7.13 |
| 52-Week Low | $2.03 |
| Open | $3.35 |
| Volume (last close) | 195.18K |
| Average Volume (3M) | 246.39K |
| 50-Day MA | $3.83 |
|---|---|
| 200-Day MA | $3.21 |
| 1-Year Change | −34.11% |
| Market Cap | 210.14M |
|---|---|
| Shares Outstanding | 65.88M |
| Price to Book (P/B) | -1.54 |
| EV/EBITDA | -20.19 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
Galectin Therapeutics at a Glance
As of the Oct 23, 2026 close, Galectin Therapeutics (GALT) has a market capitalization of $210.14M.
As of its latest reported balance sheet, it holds $13.27M in cash and securities against $137.70M of debt, a net debt position of $124.43M.
Galectin Therapeutics does not currently pay a dividend.
The share price is down 34.1% over the past year. At $3.19 (the Oct 23, 2026 close) it sits within its 52-week range of $2.02 to $7.13, below its 200-day moving average of $3.21.
Frequently Asked Questions About Galectin Therapeutics
What is the current stock price for GALT?
As of the Oct 23, 2026 close, GALT stock trades at $3.19. The 52-week range is $2.03–$7.13, with a day range of $3.16–$3.37.
What is the P/E ratio for GALT?
The P/E ratio (Price-to-Earnings) for GALT is shown in the Key Statistics section. This valuation metric helps compare Galectin Therapeutics Inc. to industry peers.
Does GALT pay dividends?
Galectin Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for GALT?
Analyst ratings and recommendations for GALT are displayed in the Analyst Consensus section, including buy/hold/sell distribution and 12-month price targets.
What is the market cap of GALT?
As of the Oct 23, 2026 close, Galectin Therapeutics's market capitalization is $210.1M, classifying it as a micro-cap company. Galectin Therapeutics operates in the Healthcare sector within the Biotechnology industry.